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A B S T R A C T
Background
In clinical trials the selection of appropriate outcomes is crucial to the assessment of whether
one intervention is better than another. Selection of inappropriate outcomes can compromise
the utility of a trial. However, the process of selecting the most suitable outcomes to include
can be complex. Our aim was to systematically review studies that address the process of
selecting outcomes or outcome domains to measure in clinical trials in children.
Methods and Findings
We searched Cochrane databases (no date restrictions) in December 2006; and MEDLINE
(1950 to 2006), CINAHL (1982 to 2006), and SCOPUS (1966 to 2006) in January 2007 for studies
of the selection of outcomes for use in clinical trials in children. We also asked a group of
experts in paediatric clinical research to refer us to any other relevant studies. From these
articles we extracted data on the clinical condition of interest, description of the method used
to select outcomes, the people involved in the selection process, the outcomes selected, and
limitations of the method as defined by the authors. The literature search identified 8,889
potentially relevant abstracts. Of these, 70 were retrieved, and 25 were included in the review.
These studies described the work of 13 collaborations representing various paediatric
specialties including critical care, gastroenterology, haematology, psychiatry, neurology,
respiratory paediatrics, rheumatology, neonatal medicine, and dentistry. Two groups utilised
the Delphi technique, one used the nominal group technique, and one used both methods to
reach a consensus about which outcomes should be measured in clinical trials. Other groups
used semistructured discussion, and one group used a questionnaire-based survey. The
collaborations involved clinical experts, research experts, and industry representatives. Three
groups involved parents of children affected by the particular condition.
Conclusions
Very few studies address the appropriate choice of outcomes for clinical research with
children, and in most paediatric specialties no research has been undertaken. Among the
studies we did assess, very few involved parents or children in selecting outcomes that should
be measured, and none directly involved children. Research should be undertaken to identify
the best way to involve parents and children in assessing which outcomes should be measured
in clinical trials.
The Editors’ Summary of this article follows the references.
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Introduction
The purpose of a clinical trial is to determine the beneﬁts
and harms of an intervention. This determination is made by
measuring the effects of different treatments on outcomes.
The selection of appropriate outcomes, therefore, is crucial
to the assessment of whether one intervention is better than
another. This review relates to studies that explain how
outcomes have been selected for use in clinical trials in
children younger than 16 years of age. For the purposes of
this review we deﬁne children by age rather than by the literal
meaning of offspring.
What Outcomes Measure—The Impact of Illness on a
Patient’s Life
Models have been developed that describe the effects of a
disease on a patient, for example the biopsychosocial model
and the World Health Organisation framework of impair-
ment, disability, and handicap [1,2]. Although these models
differ in many ways, an underlying theme is that illnesses
affect more than one aspect of a patient’s life. For example,
asthma may affect a child’s life by way of troublesome daily
symptoms even when the child is ‘‘well,’’ exacerbations,
disrupted school attendance, and abnormal lung function.
Each of these effects of asthma on the child’s life is potentially
amenable to improvement after starting an intervention. In
clinical trials, the extent to which an intervention affects the
impact of an illness on a patient’s life is reﬂected by
measuring change in outcomes.
For the purpose of this review, we clarify our terminology
in Table 1.
Outcomes can reﬂect various effects of an intervention.
They may directly measure a deﬁnitive clinical change, such
as death or hospital admission. Surrogate outcomes, which
are sometimes used in lieu of a deﬁnitive clinical outcome,
aim to capture the effects of an intervention without having
to wait for the clinical change to actually occur. In other
words, they are proximal to the clinical outcome on the
disease pathway, so a change can be detected sooner. They
may be a measure of intermediate health status, which may be
used to predict future health status; for example, glycosylated
haemoglobin is used as a measure of current disease control
in patients with diabetes mellitus, and has been shown to be a
useful predictor of future control [3]. A surrogate outcome
may even be an assumed or established risk factor that
actually impacts on disease progression; for example, neo-
natal intraventricular haemorrhage, which is a recognised
complication of prematurity, is thought to alter brain
development in the early stages of life and predispose babies
to developmental problems in childhood. There are valida-
tion criteria that should be fulﬁlled before a surrogate
outcome can be conﬁdently used in place of a deﬁnitive
clinical outcome in clinical trials [4].
An outcome domain may be represented by a variety of
outcomes. The domain of health care utilisation, for example,
may be reﬂected by number of visits to a general practitioner,
number of hospital admissions, or days spent in hospital.
Conversely, outcomes may be relevant to more than one
domain. For example, in clinical trials of children with
asthma, the outcome ‘‘number of courses of rescue predni-
solone therapy’’ may be a measure of health care utilisation,
or could alternatively represent change in the domain
‘‘exacerbations.’’ These various ‘‘levels’’ of outcome measure-
ment are illustrated schematically in Figure 1.
Selecting Outcomes for Use in Clinical Trials
Clinical trials are ‘‘only as credible as their outcomes’’ [5],
so when designing a clinical trial, the decision as to which
outcomes should be measured is crucial. The selection of
inappropriate outcomes can lead to wasted resources or
misleading information that overestimates, underestimates,
or completely misses the potential beneﬁts of an interven-
Table 1. Definitions Used in Review
Terminology Description Examples
Outcome domain A relatively broad aspect of the effect of illness on a child,
within which an improvement may occur in response to
an intervention. In general these domains may not be directly
measurable themselves, so outcomes are selected to assess
change within them.
(1) In clinical trials of children with diabetes,
outcome domains may include acute metabolic
complications, long-term glucose control, renal
damage, or effects on schooling.
(2) In clinical trials of children with asthma, outcome
domains may include lung function, health care
utilisation, and symptom control
Outcome/endpoint A measurable variable within an outcome domain. The outcome
can be measured at a variety of time points, which must be clearly
stated by authors of clinical trials.
(1) Absolute FEV1 expressed as change from baseline
(2) Number of admissions to hospital within a six month period
(3) Time to first seizure after starting an antiepileptic intervention
Composite outcome An outcome that encompasses more than one domain. A
composite outcome may span more than one outcome domain.
These are sometimes referred to as global outcomes, because they
theoretically measure several aspects of the impact of illness on a patient.
In the NIMH Collaborative Multisite Multimodal Treatment Study
of Children with Attention Deficit/Hyperactivity Disorder, response
to treatment was measured by a composite outcome comprising
outcomes that reflect clinical outcome, academic functioning,
effects on family life, and other domains [37]
Outcome measure A scale, scoring system, questionnaire, or other tool used for
measuring an outcome. They may be an amalgamation of more than
one outcome within an outcome domain, such as a score based on
a variety of symptoms. More than one outcome measure may be
possible to use to represent change in an outcome.
(1) The Paediatric Asthma Quality of Life Questionnaire [38]
(2) Childhood Health Assessment Questionnaire [39]
(3) Gastro-esophageal Reflux Disease Symptom Questionnaire [40]
doi:10.1371/journal.pmed.0050096.t001
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tion. Examples of these problems are well documented [6,7].
Investigators can select from a range of several potential
outcomes spanning different domains when they are design-
ing a clinical trial, however, and the process of determining
which outcome to use can be complex. The difﬁculty of
selecting the most appropriate outcomes for use in a clinical
trial is reﬂected in the fact that in several ﬁelds of clinical
research there is much heterogeneity between clinical trials
of speciﬁc diseases regarding exactly which outcomes to
select [8,9]. Some of the factors underlying this uncertainty
may be that for these conditions there is uncertainty about
which outcome domains are most relevant to patients, that
the performance characteristics of potential outcomes have
not been established, or that as the general care of patients
has improved, previously used outcomes are no longer
relevant.
Since the late 1980s there have been attempts, notably in the
ﬁeld of rheumatology (Outcome Measures in Rheumatology,
http://www.omeract.org/), to develop ‘‘core sets’’ of outcomes
that should be measured in all clinical trials of speciﬁc
conditions. These studies generally use techniques to ascertain
a consensus opinion from clinical experts as to which
outcomes are most suitable for use in clinical trials. The three
commonly used consensus techniques are nominal group
technique (NGT), which entails structured face-to-face dis-
cussion with the aim of developing a solution to a speciﬁc
problem, followed by a vote on the issue; Delphi technique, in
which opinions are sought from individuals and the collated
results are fed back to the group as a whole, to generate further
discussion and ﬁnally reach an agreement; and semistructured
discussion based around broader discussion points.
The objective of this project was to systematically review
studies that address the process of selecting which outcome
domains or outcomes to measure in clinical trials in children
under 16 years of age. We have restricted this review to
studies in children for the following reasons. In clinical
research there is increasing recognition that children are not
merely ‘‘small adults,’’ and the methodology of conducting
research in a paediatric population should be tailored
accordingly. We anticipate that one way of determining
which outcomes to use, in addition to the consensus
techniques described above, may be to ascertain the opinions
of both children and their parents regarding what they think
are important aspects of their disease. This process poses
unique challenges that may not be relevant when conducting
similar research in adults with a particular condition, so it is
appropriate to speciﬁcally review studies pertaining to
outcome domain and outcome selection in clinical trials in
children.
Methods
Study Selection
Included studies. We decided that the following types of
studies would be eligible for inclusion in the review: (1)
Studies that develop or apply methodology for selecting
outcome domains or outcomes to be used in clinical trials in
children younger than 16 years of age, and (2) systematic
reviews of these articles.
Excluded studies. We excluded the following types of
studies. (1) Studies that do not speciﬁcally state that the
outcomes are appropriate for use in a paediatric population.
(2) Studies that discuss how to measure, rather than how to
select, an outcome domain or outcome for use in clinical
trials. This category includes studies discussing performance
characteristics of outcomes or instruments for measuring
them. (3) Studies relating to clinical trials that assess
interventions given to adults by measuring outcomes in
children, for example the selection of neonatal outcomes to
assess care given to their mothers.
Identification of Studies
In December 2006 we searched Cochrane databases (no
date restrictions), and in January 2007 we searched MEDLINE
(1950 to 2006; http://www.ovid.com/site/catalog/DataBase/901.
jsp?top¼2&mid¼3&bottom¼7&subsection¼10), CINAHL (1982
to 2006; http://www.cinahl.com/), and SCOPUS (1966 to 2006;
http://www.scopus.com/). SCOPUS is a platform that enables
the searching of several databases, including EMBASE,
simultaneously. We used the following abbreviated search
strategy: ‘‘Clinical trials’’ AND ‘‘Outcomes’’ AND ‘‘Children’’
AND ‘‘methodology’’. Details of the full search strategy are
included in Table S1.
The abstracts produced by the searches were initially
screened twice by one reviewer. The full texts of all
potentially relevant articles were obtained, and these were
assessed with regard to the eligibility criteria. Data were
extracted from the studies that met all the eligibility criteria.
A second reviewer, who was blinded to the ﬁrst reviewer’s
assessment of the abstracts, independently screened a data-
base of abstracts that comprised all the abstracts for which the
ﬁrst reviewer obtained full text, plus a selection of abstracts
rejected at the initial screening stage by the ﬁrst reviewer. The
purpose of this approach was to check the sensitivity of the
initial screening process that had been performed in full by
the ﬁrst reviewer. A sample, rather than the complete set, was
selected due to resource constraints. Any disagreements
between the reviewers were resolved by discussion.
This process led to a list of studies for which full text were
obtained. Both reviewers then scrutinised these articles for
the predetermined inclusion and exclusion criteria in order
to determine which studies should be included in the
systematic review.
We then emailed a list of the studies we had identiﬁed to
the Clinical Study Group (CSG) members of the Medicines for
Children Research Network (MCRN) and asked if they knew
of any other relevant studies, published or unpublished, that
should be included. The CSG constitutes a multidisciplinary
group of clinical experts with a strong interest in the
planning of clinical trials within their specialities.
Data Extraction
The following data were extracted by one reviewer (IS) and
checked independently by the second reviewer (LJ): (1)
Figure 1. Levels of Outcome Measurement
doi:10.1371/journal.pmed.0050096.g001
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Condition for which the outcome domains or outcomes are
discussed; (2) Description of the method; (3) People involved
in selecting outcome domains or outcomes; (4) Outcome
domains or outcomes selected; (5) The geographical setting of
the collaborations, ascertained either by reading the text or,
where listed, the names and institutions of people involved in
the collaborations; (6) Limitations of the method as deﬁned
by the authors
Assessment of Methodological Quality
The methodological quality of the studies was assessed by
one author (IS). If a study developed or used methodology to
select an outcome domain or an outcome, the article was
assessed in terms of whether the method was described in
sufﬁcient detail to allow a reader to utilise it.
If a study described a consensus procedure, the following
points were noted: (1) Is the selection process and areas of
expertise of the participants described?; (2) Is the process of
coming to consensus described in detail?
We searched for a validated assessment tool for critically
appraising consensus statements but we could not identify
one. We therefore asked two experts, one with experience of
qualitative research and the other with experience of
participating in a consensus statement exercise to advise on
this methodological assessment checklist.
For systematic reviews of studies which used methodology
for selecting outcomes it was agreed that we would use the
Critical Appraisal Skills Programme Systematic Review
Appraisal tool for assessing their methodological quality
(http://www.phru.nhs.uk/Pages/PHD/resources.htm).
Data Analysis and Presentation of Results
For synthesis of data we described the studies narratively
and tabulated their characteristics. Consistent with the
nature of the data, the results are presented in textual format.
Results
Description of Studies
The initial database search identiﬁed 8,889 potentially
relevant abstracts, of which 70 articles were retrieved in full
and, ﬁnally, 25 included in the full review, as depicted by the
ﬂowchart in Figure 2.
In total, 57 full-text articles were reviewed and subse-
quently excluded. Of the 57 studies 19 were excluded because
the authors did not use methodology for selecting outcomes
(e.g., a review article based on personal opinion), 18 because
the study related to how to measure outcomes rather than
which ones to select, ten because the study made no mention
of outcome selection, six because the study did not
speciﬁcally state that the outcomes which were selected were
relevant to children, and four that described consensus
statements relating to clinical practice rather than clinical
trial design. The reasons for exclusion of each individual
study are presented in Table S2.
In addition, 13 speciﬁc articles were suggested by the
members of the MCRN CSGs in response to our email query.
One of these articles summarised the work of a collaboration
that had been identiﬁed by the literature search but did not
describe the methodology used by the group in sufﬁcient
detail to warrant inclusion in the full review, so is added as an
additional reference [10]. The other studies identiﬁed were
not deemed to be eligible for the full review.
Agreement between Reviewers
The second reviewer was provided with a database of 100
abstracts. These included 70 for which the ﬁrst reviewer
thought full text should be retrieved, and a randomly selected
sample of 30 abstracts that had been excluded by the ﬁrst
reviewer at the abstract screening stage.
The second reviewer agreed that all 30 abstracts rejected at
the abstract screening stage were appropriately excluded by
the ﬁrst reviewer.
Of the 70 abstracts for which full text was obtained by the
ﬁrst reviewer, the second reviewer agreed with 61, and
disagreed with nine. After discussion it was agreed that all
nine should be retrieved in full based on the abstract. Of
these, eight were excluded after reading the full text and one
was included.
Following full text review there was complete agreement
between the second and ﬁrst reviewer about the 25 included
and 45 excluded abstracts. The second reviewer also checked
all the data that had been extracted by the ﬁrst reviewer, and
agreed completely with the tabulated characteristics of the
studies.
Included Studies
The 25 articles included in the full review represented the
work of 13 collaborative groups. The characteristics of each
study are included in Table S3, and summarised in Table 2.
Six of these groups (Grifﬁths et al. [11], Ramsey et al. [12],
Pavletic et al. [13], Giannini et al. [14], International Myositis
Assessment and Clinical Studies group (IMACS) [15], and
Paediatric Rheumatology International Trials Organisation
(PRINTO) [16]) aimed to develop a consensus statement
speciﬁcally about outcome measures that should be used in
clinical trials of certain medical conditions. Five groups
(Carlson et al. [17], Goldstein et al. [18], LaFrance et al. [19],
Neonatal Drug Development Initiative (NDDI) [20–24], and
West Delphi group [25]) discussed which outcomes to
measure as part of workshops which addressed wider clinical
trial design issues. One group (Smith et al. [26]) aimed to
ascertain the opinions of clinical experts about which
Figure 2. Study Flowchart
doi:10.1371/journal.pmed.0050096.g002
PLoS Medicine | www.plosmedicine.org April 2008 | Volume 5 | Issue 4 | e960572
Selecting Outcomes for Paediatric Trials
outcomes to measure in clinical trials in children with
asthma. One group (DeRouen et al. [27]) ascertained the
opinions of experts about which outcome to measure in a
speciﬁc safety trial of two interventions used in paediatric
dental restoration. Our search identiﬁed no systematic
reviews of studies that had selected outcome measures for
use in clinical trials.
Most groups appeared to comprise an international
collaboration of participants. Eight groups were based in
the US (Ramsey et al. [12], Goldstein et al. [18], La France et al.
[19], the NDDI [20–24], Carlson et al. [17], Grifﬁths et al. [11],
DeRouen et al. [27], and Pavletic et al. [13]). One group was
based in Europe (West Delphi group [25]). One group was
based in Australasia (Smith et al. [26]). The three rheumatol-
ogy collaborations [14–16] seem to have been based mainly in
the US, but it appears that many of the leaders of these
groups were based in Europe.
Methodological Quality of Studies
General observations regarding the methodological quality
of the studies are provided in this section. Methodological
features of each speciﬁc study are provided in Table S4.
Reporting of methodology. Of the 13 collaborations four
used structured techniques to formulate a consensus (Gian-
nini et al. [14], West Delphi group [25], PRINTO [16], and
IMACS [15]); these were NGT and/or Delphi technique. Of
these groups, three described the process very clearly. Eight
collaborations came to a consensus by structured discussion,
but without using structured consensus formulation techni-
ques mentioned above (Goldstein et al. [18], Ramsey et al. [12],
LaFrance et al. [19], NDDI [20–24], Carlson et al. [17], Grifﬁths
et al. [11], De Rouen et al. [27], and Pavletic et al. [13]). All of
these groups described the discussions in some detail. One
group sought opinions in a questionnaire-based survey, and
the methodology used for this study was described in
sufﬁcient detail to be able to repeat the study (Smith et al.
[26]).
Selection of participants. All groups described the back-
ground of their participants. Only two of these groups
described in detail the process by which it was decided
speciﬁcally which individuals would be involved (West Delphi
group [25] and Smith et al. [26]).
Methods Used to Select Outcomes
The following techniques were used to ascertain expert
opinion concerning which outcomes ought to be measured in
clinical trials of children with speciﬁc conditions.
Delphi technique. As described earlier, Delphi technique is
one method of reaching a consensus opinion that relies on
one person collating the views of each individual in a group,
collating the results, and feeding these back to the whole
group [28]. Statements made by participants at each stage of
the process can be used to formulate the next round of
questions. This technique has been used since the 1950s.
Three groups utilised this method as follows.
The West Delphi group [25] used this technique to develop
a core set of outcomes for use in clinical trials of children
suffering from infantile spasms. The whole process was
conducted by email over six rounds. In round one a group
of 133 invited participants, of which 42 responded, were
asked multiple-choice questions covering various aspects of
clinical trial design, including outcomes. In round two a
separate set of multiple-choice questions was provided,
having fed the results of round one back to the group. At
this stage the participants were also invited to comment and
provide their personal opinions regarding outcomes. In
round three statements were formulated from those re-
sponses in rounds one and two that had represented majority
opinion. Participants were invited to respond as to whether
they agreed or disagreed with these statements. For round
four the statements were modiﬁed, and participants com-
Table 2. Summary of Included Studies
Speciality Condition Authors
Critical care Sepsis Goldstein 2005 [18]
Dentistry Dental restoration DeRouen 2002 [27]a
Gastroenterology Crohn disease Griffiths 2005 [11]
Haematology/bone transplant medicine GVHD Pavletic 2006 [13]
Neonatology Apnoea Finer 2006 [22]b,c
Cardiac instability Short 2006 [24]b,c
Pain Anand 2005 [41], Anand 2006 [20]b,c
Postoperative cardiac dysfunction Roth 2006 [23]b,c
Seizures Clancy 2006 [21]b,c
Neurology Infantile spasms Lux 2004 [25], Osborne (on behalf of the West Delphi group) 2001 [42]
Psychiatry Bipolar affective disorder Carlson 2003 [17]
Nonepileptic seizures La France 2006 [19]b
Respiratory medicine Asthma Smith 1996 [26]
Cystic fibrosis Ramsey 1994 [12]
Rheumatology IIM Miller 2001 [15], Rider 2002 [43], Rider 2003 [33], Rider (on behalf of IMACS) 2004
[44], Oddis 2005 (describing the work of IMACS) [45]
SLE Ruperto 2003 [16], Ruperto 2004 [30], Ruperto (on behalf of PRINTO) 2006 [46]
Rheumatoid arthritis Giannini 1997 [14]
aConcerned the selection of outcomes for use in a specific clinical trial.
bConcerned the selection of outcomes which could be used in clinical trials of children with clinical features of an underlying condition.
cCollaboration working on behalf of the Neonatal Drug Development Initiative (NDDI).
doi:10.1371/journal.pmed.0050096.t002
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mented on their suitability and content. Rounds ﬁve and six
consisted of formulation of a draft and, subsequently, a ﬁnal
paper that were altered following comments from the group.
The IMACS [15] group used a Delphi technique to develop
a core set of outcome domains and outcomes for use in
clinical trials in children with inﬂammatory myopathy. The
actual process itself is not described in detail in the article,
but authors stated that the group consisted of ‘‘more than
100’’ members.
The PRINTO [16] group used a Delphi technique over two
sequential questionnaire-based surveys to identify which
variables should be measured in clinical trials of children
with SLE. In the ﬁrst questionnaire they asked 267 partic-
ipants to indicate up to ten variables they judged as clinically
most important. In the second questionnaire, the facilitators
listed those indicators that had been suggested by at least ten
responders, and asked the participants to rank in order their
top ten choices.
Nominal group technique. NGT is a technique based on
structured face-to-face discussion developed in the early
1970s. Having discussed a problem, with a view to providing
potential solutions, the participants vote on the options
presented, and ultimately a consensus is reached [29]. Two
groups utilised this technique.
PRINTO [16] used NGT to discuss speciﬁc issues regarding
the potential outcomes identiﬁed by the initial Delphi
technique discussions described earlier. The NGT exercise
had ﬁve objectives, which were tackled by a group of 40
participants: (1) to classify the proposed outcomes into
‘‘domains’’; (2) to classify the outcomes into ‘‘concepts of
disease activity’’; (3) to select the outcome domains that
should be measured in clinical trials; (4) to select the
outcomes that should be used to measure these domains;
and (5) to discuss speciﬁc design issues of the prospective
validation phase of the study.
Giannini et al. [14] used NGT to select from a set of
potential outcomes a preliminary core set of six. The process
used is not described in further detail in the study. The initial
list of potential outcomes had been identiﬁed by sending a
questionnaire to a 16-member advisory council.
Semistructured discussion. Most groups did not use
structured techniques of consensus development such as
Delphi or NGT, but rather came to consensus by discussion at
meetings or workshops. As mentioned earlier, some collab-
orations—for example those groups discussing methodology
issues in studies of neonates—discussed outcome selection
broadly, as part of wider discussions about neonatal clinical
trial designs. Other groups—for example, the group selecting
outcome measures for use in an individual clinical trial of
dental restoration—conducted very focussed discussions
about very speciﬁc problems.
Questionnaires. Smith et al. [26] sent questionnaires to 39
health care professionals and researchers with expertise in
asthma to ask which outcomes they would use for a variety of
clinical, research, and public health scenarios, including
questions about which outcome they would use in clinical
trials of acute and preventative asthma medication. Three
groups (Giannini et al. [14], West Delphi [25], and PRINTO
[16]) used questionnaires as part of the process of ascertain-
ing the opinions of experts, mainly in the preliminary phases
of the consensus process.
People Involved in Selecting Outcomes
Clinical experts. All 13 groups included people with clinical
expertise in the ﬁelds for which they were selecting outcomes.
Eight groups speciﬁcally mention the involvement of clini-
cians in both paediatric and adult health care.
Research experts. All groups appeared to include members
who were experienced in research in the clinical condition
for which outcomes were being selected. In addition to these
clinical research experts, some groups also included bio-
statisticians and epidemiologists. Three groups involved
experts from other clinical research areas who had experi-
ence in collaborations that had selected outcomes for clinical
trials of other medical conditions. More collaborations may
have used experts from this category, but may have referred
to them generically as ‘‘research experts,’’ so it is difﬁcult to
quantify exactly how many groups used this approach.
Patients or parents. Three groups ascertained the opinions
of parents of children with medical conditions as to which
outcomes they thought should be measured, but no group
involved children directly. IMACS [15] involved two patient
support group leaders who had a child who suffered from
inﬂammatory myopathy. Although this was not explicitly
stated in the text, we elicited this information by searching
for the names of the support group leaders on an internet
search engine. Carlson et al. [17] also involved ‘‘representa-
tives of families with affected children’’ in their discussions
about outcomes in clinical trials of children with bipolar
affective disorder. Pavletic et al. [13], at the end of their
report, acknowledge ‘‘patients and patient and research
advocacy groups.’’ The level of involvement of these people
was not described in detail in any of these articles.
Industry and drug regulatory authority representatives.
Three groups (Carlson et al. [17], Ramsey et al. [12], and the
NDDI [20–24]) speciﬁcally mention that representatives from
industry or the Food and Drug Administration (FDA) were
present. The NDDI is described as a collaboration between
the FDA and ‘‘neonatal experts and colleagues, representing
industry and academia’’ [10]. Carlson describes invited
participants in the group selecting outcomes for clinical
trials of children with bipolar disorder as including ‘‘phar-
maceutical industry sponsors with an interest in mood
stabilizer products, staff of the FDA and their counterparts
from regulatory agencies in Canada and the European
Union’’ [17]. The Cystic Fibrosis Foundation sponsored a
consensus conference that also included ‘‘representatives
from both the Cystic Fibrosis Foundation and the U.S. Food
and Drug Administration’’ [12].
Techniques Used to Validate Outcomes
Three groups made some attempt to validate the outcomes
they had selected.
Giannini et al. [14] assessed the multicollinearity and
redundancy of a core set of outcomes for use in clinical
trials of children with rheumatoid arthritis by measuring
them in a group of children in a clinical practice setting, and
using a database from a previous observational cohort study.
The acceptability of the core set of outcomes to a wider group
of clinicians was assessed by sending a questionnaire to an
international selection of rheumatologists seeking their
reactions to the outcomes.
The IMACS group retrospectively assessed the validity,
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reliability, and responsiveness of the outcomes they had
selected by reviewing available literature on the topic [15].
The PRINTO group prospectively validated the core set of
outcomes they had produced for clinical trials of children with
SLE [30]. This was done bymeasuring the outcomes in patients
in a clinical out patients setting who were being started on
new modalities of treatment for their condition. In this way
the authors aimed to ‘‘mirror’’ a clinical trial setting. The
feasibility, discriminative ability, validity, and internal con-
sistency of the core set of outcomes were assessed in this way.
All three of these groups also developed ‘‘deﬁnitions of
improvement,’’ based on the degree of change within each
outcome, which could be used as a dichotomous index in
clinical trials to determine whether patients had beneﬁted
from the treatment they had received. This was done in all
cases by developing a set of ‘‘paper patient proﬁles,’’ and
asking a group of experts whether or not they thought the
patient had improved. A set of potential deﬁnitions of
improvement was then narrowed down to a ﬁnal deﬁnition by
way of consensus formation techniques.
Which Outcomes Were Selected by the Groups?
In Table S5 we summarise the outcomes that were selected
by each group, categorised into the following outcome
domains: disease activity; disease complications; adverse
effects of therapy; functional status; social outcomes, family
outcomes and Quality of Life; resource utilisation.
Discussion
To our knowledge this is the ﬁrst systematic review of
studies that addressed selection of outcomes for use in
clinical trials in children.
We identiﬁed 13 groups formed to address the issue of
selecting outcomes for use in paediatric clinical trials. Certain
groups—notably, those who have selected outcomes for
clinical trials of children with rheumatological conditions—
have speciﬁcally highlighted that it is inappropriate simply to
use the outcomes utilised in adult clinical trials in a
paediatric population.
We identiﬁed three methods used for reaching consensus,
namely NGT, Delphi technique, and semistructured discus-
sion. Many groups used a multidisciplinary approach to the
problem of outcome selection, including researchers with
experience of clinical trial design, statisticians, and clinicians.
Some groups also involved representatives from industry or
drug regulatory authorities, but the nature of their involve-
ment is not evident from reading the reports.
No group among the studies we reviewed directly involved
children in the process of selecting outcomes. As the aim of
clinical trials should be to determine whether patients
experience important beneﬁts from an intervention, it was
notable that we did not identify any studies that had directly
asked children what they considered to be the most relevant
outcome domains or outcomes. In the United Kingdom steps
are being taken to involve consumers in medical research. A
major initiative is the James Lind Alliance (http://www.
lindalliance.org/), a collaboration with the aim of ascertaining
from patients what they think are the most pressing research
priorities for various conditions. Determining appropriate
outcomes for paediatric studies is thus another area in which
consumer involvement in clinical trial design should be
encouraged. The difﬁculties of undertaking this task, how-
ever, should not be underestimated [31].
Robustness and Limitations of the Review
Our review was conducted in a rigorous, systematic
manner. Two reviewers adhered to strict eligibility criteria
to determine which studies should be included. Although the
sample of excluded papers checked by the second reviewer
represented a small proportion of all the ineligible studies, we
concluded that agreement between the reviewers was
adequate. We determined that a smaller proportion of
excluded studies would be sufﬁcient for quality assurance as
compared to a review in which we were meta-analysing the
results of clinical trials; possible missed studies were
considered an acceptable tradeoff.
There were recurring features of the methodology and
reporting quality of the consensus statements that may have
compromised the scientiﬁc validity of the studies we
identiﬁed. Most studies that described formation of a
consensus statement did not explain in sufﬁcient detail two
key aspects of the process—namely, the method used to select
group participants, and the process by which consensus was
reached. Insufﬁcient information was given to determine the
level of involvement of certain groups involved in the
research, particularly industry representatives, drug regula-
tory authority representatives, and parents of affected
children.
Although the 8,889 abstracts identiﬁed were screened
twice, it may be possible that some relevant studies were
missed. The types of studies that may not have been identiﬁed
at this stage include clinical trials that did not describe in the
abstract how the authors selected their outcomes, but
subsequently in the full text may have mentioned the process
used. It is also possible that some studies may have been
missed by not searching the ‘‘grey’’ literature such as
unpublished conference proceedings.
We excluded studies that did not state speciﬁcally that they
selected outcomes for use speciﬁcally in clinical trials in
children. Our reason for this exclusion was that such studies
should involve patients themselves, and the unique challenges
of doing this in children warrants the separation of adult and
paediatric studies. Another group of studies excluded were
those concerned with the development of assessment tools
for outcomes such as quality of life. Although this work is
crucial for designing valid assessment tools, and will to some
degree ascertain from children how illness affects their life,
these studies focussed on how to measure an outcome rather
than what outcome to measure.
Another set of studies outside the scope of this review were
those relating to the selection of outcomes that are measured
in newborns as a surrogate measure of maternity care given
to women. For example, one way of evaluating the efﬁcacy of
antenatal care is to measure outcomes in babies such as rates
of neonatal infection [32]. Similarly, studies in which out-
comes were selected that evaluate the effect of interventions
given to children by measuring effects on the family were not
systematically sought. We did, however, identify two studies in
which such outcomes were selected [19,33].
Core Outcomes
If implemented, the studies we have identiﬁed should
reduce the impact of inappropriate outcome selection on the
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quality of the evidence provided by individual clinical trials.
The development of a universally agreed core set of outcomes
for a condition could, as well as improving the quality of
individual clinical trials, lead to less heterogeneity between
trials. One problem associated with nonuniform reporting of
outcomes is outcome reporting bias, a phenomenon that
results from the selective reporting of some outcomes but not
others, depending on the results [34,35].
One cause of outcome reporting bias may be that statisti-
cally insigniﬁcant results are more likely to be left out of the
report, so outcomes at the planning stage of a trial that might
otherwise have been deemed clinically relevant are deemed
‘‘irrelevant’’ after data analysis, rendering the published
literature a biased and selective representation of the
research [36]. Disease-speciﬁc, universally agreed core sets of
outcomes that should be measured and reported in all clinical
trials of a speciﬁc condition, regardless of statistical signiﬁ-
cance, have been advocated as a solution to this common
problem [35]. Uniform selection of outcomes would also make
interpretation of results and comparison across trials simpler,
hence making meta-analyses easier and more powerful [9].
European Drug Regulation
It is increasingly recognised that there is a need for high-
quality paediatric clinical trials, and the development of
Paediatric Investigation Plans (PIPs) is one of the changes in
drug regulation in Europe that should facilitate this goal. The
PIP is a detailed outline of the research, submitted to the
European Medicines Agency (EMEA), that would be needed to
investigate the potential beneﬁts and harms of medications for
use in children. If a drug company were to be involved in the
writing and implementation of a PIP, they would be eligible
for marketing rewards in the form of prolonged patent
protection and market exclusivity. When a PIP is submitted,
the endpoints selected for the trial must be clearly stated and
their appropriateness described (http://www.emea.europa.eu/
htms/human/paediatrics/pips.htm). The studies we have iden-
tiﬁed that suggest to trialists which outcomes to measure
should be of use to people designing a PIP, and it is possible
that the types of studies we have identiﬁed may become more
popular as drug companies seek to take advantage of the
beneﬁts of conducting high-quality clinical trials.
The new standards for conducting clinical trials of
investigational medicinal products set by the EMEA aim to
improve the quality of paediatric research. In order to obtain
a license for a drug, it must be investigated according to these
guidelines http:/ /www.emea.europa.eu/htms/human/
humanguidelines/efﬁcacy.htm). In July 2007, of the 13
paediatric conditions identiﬁed in this review the EMEA
Web site included guidelines for one (juvenile idiopathic
arthritis) and a concept paper discussing the need for
guidelines for another (cystic ﬁbrosis).
The Selection of Outcomes for Use in Children
It is appropriate that some aspects of study design in
clinical trials in children differ from equivalent studies
performed in adults, and selection of outcomes is one such
issue that trialists should consider. In certain situations
outcome selection may be similar between the two groups,
and some outcomes could be appropriately transposed from
adult studies into trials in paediatric populations either in
their original state or with slight modiﬁcation. The danger,
however, of not acknowledging the differences between
children and adults with the same disease is that the overall
validity of trial results could be compromised. Grifﬁths et al.
[11], when discussing which outcomes to measure in clinical
trials of children with Crohn disease, highlight that the
importance of linear growth is ‘‘unique to pediatric patients.’’
Another example of an outcome exclusive to children is the
assessment of neurodevelopment. Other differences between
adults and children that may preclude the use of the same
outcomes for both groups include distinct disease patho-
genesis, different clinical features and natural history,
variations in physiological and psychological outcomes, and
contrasting roles within the contexts of families and society
in general that may preclude the use of the same outcomes.
Unanswered Questions
The best strategy for selecting outcomes for clinical trials
in children is currently not known, and future research in this
area is warranted. One important question relates to the
involvement of children and parents in the formulation of
consensus statements. It seems logical that their involvement
would help determine the most appropriate outcomes to
measure, but there is no evidence to substantiate this
hypothesis, nor is there a framework that could recommend
the best strategy for involvement. Another area for research
is the investigation of the relative strengths and weaknesses of
the consensus formation techniques identiﬁed here when
applied to the problem of selecting outcomes for paediatric
studies.
In summary, we have reviewed studies that address the
process of selecting outcomes for clinical trials in children.
Although it is commendable that there are existing collabo-
rations in several clinical areas, future work in this area may
be improved by involving children and parents in the process.
The studies identiﬁed by this review will go some way to
improving the quality of paediatric research, but further
research is justiﬁed and urgently needed.
Conclusions
Implications for the practice of designing clinical trials. We
identiﬁed 13 paediatric conditions for which work has been
done to determine which outcomes should be measured in
clinical trials. When designing clinical trials in these
conditions, this work should make the selection of outcomes
easier and more uniform.
Implications for research. Although some work on how to
select outcomes in paediatric trials has been published in a
few clinical areas, there is a need for similar work to be
conducted in other areas. Very little work has been done that
involves parents or children in assessing which outcomes
should be measured in clinical trials; future research should
be undertaken to address this deﬁciency.
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Editors’ Summary
Background. When adult patients are given a drug for a disease by their
doctors, they can be sure that its benefits and harms will have been
carefully studied in clinical trials. Clinical researchers will have asked how
well the drug does when compared to other drugs by giving groups of
patients the various treatments and determining several ‘‘outcomes.’’
These are measurements carefully chosen in advance by clinical experts
that ensure that trials provide as much information as possible about
how effectively a drug deals with a specific disease and whether it has
any other effects on patients’ health and daily life. The situation is very
different, however, for pediatric (child) patients. About three-quarters of
the drugs given to children are ‘‘off-label’’—they have not been
specifically tested in children. The assumption used to be that children
are just small people who can safely take drugs tested in adults provided
the dose is scaled down. However, it is now known that children’s bodies
handle many drugs differently from adult bodies and that a safe dose for
an adult can sometimes kill a child even after scaling down for body size.
Consequently, regulatory bodies in the US, Europe, and elsewhere now
require clinical trials to be done in children and drugs for pediatric use to
be specifically licensed.
Why Was This Study Done? Because children are not small adults, the
methodology used to design trials involving children needs to be
adapted from that used to design trials in adult patients. In particular,
the process of selecting the outcomes to include in pediatric trials needs
to take into account the differences between adults and children. For
example, because children’s brains are still developing, it may be
important to include outcome measures that will detect any effect that
drugs have on intellectual development. In this study, therefore, the
researchers undertook a systematic review of the medical literature to
discover how much is known about the best way to select outcomes in
clinical trials in children.
What Did the Researchers Do and Find? The researchers used a
predefined search strategy to identify all the studies published since
1950 that examined the selection of outcomes in clinical trials in children.
They also asked experts in pediatric clinical research for details of
relevant studies. Only 25 studies, which covered several pediatric
specialties and were published by 13 collaborative groups, met the
strict eligibility criteria laid down by the researchers for their systematic
review. Several approaches previously used to choose outcomes in
clinical trials in adults were used in these studies to select outcomes. Two
groups used the ‘‘Delphi’’ technique, in which opinions are sought from
individuals, collated, and fed back to the individuals to generate
discussion and a final, consensus agreement. One group used the
‘‘nominal group technique,’’ which involves the use of structured face-
to-face discussions to develop a solution to a problem followed by a
vote. Another group used both methods. The remaining groups (except
one that used a questionnaire) used semistructured discussion meetings
or workshops to decide on outcomes. Although most of the groups
included clinical experts, people doing research on the specific clinical
condition under investigation, and industry representatives, only three
groups asked parents about which outcomes should be included in the
trials, and none asked children directly.
What Do These Findings Mean? These findings indicate that very few
studies have addressed the selection of appropriate outcomes for clinical
research in children. Indeed, in many pediatric specialties no research has
been done on this important topic. Importantly, some of the studies
included in this systematic review clearly show that it is inappropriate to
use the outcomes used in adult clinical trials in pediatric populations.
Overall, although the studies identified in this review provide some
useful information on the selection of outcomes in clinical trials in
children, further research is urgently needed to ensure that this process
is made easier and more uniform. In particular, much more research must
be done to determine the best way to involve children and their parents
in the selection of outcomes.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050096.
 A related PLoS Medicine Perspective article is available
 The European Medicines Agency provides information about the
regulation of medicines for children in Europe
 The US Food and Drug Administration Office of Pediatric Therapeutics
provides similar information for the US
 The UK Medicines and Healthcare products Regulatory Agency also
provides information on why medicines need to be tested in children
 The UK Medicines for Children Research Network aims to facilitate the
conduct of clinical trials of medicines for children
 The James Lind Alliance has been established in the UK to increase
patient involvement in medical research issues such as outcome
selection in clinical trials
PLoS Medicine | www.plosmedicine.org April 2008 | Volume 5 | Issue 4 | e960578
Selecting Outcomes for Paediatric Trials
